Precigen (PGEN) Income towards Parent Company (2012 - 2026)
Precigen's (PGEN) quarterly Income towards Parent Company came in at -$7.9 million in Q1 2026, up 85.36% year-on-year from -$4.3 million in Q1 2025, and up 66.26% on a QoQ basis from -$23.5 million in Q4 2025.
Precigen (PGEN) Income towards Parent Company (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 14 years of Income towards Parent Company data on file, last reported at -$7.9 million in Q1 2026.
- On a quarterly basis, Income towards Parent Company rose 85.36% year-over-year to -$7.9 million in Q1 2026; TTM through Mar 2026 was -$204.4 million, a 30.49% decrease from a year earlier, with the FY2025 full-year figure at -$250.6 million, changed N/A from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$7.9 million, up from -$23.5 million in the prior quarter.
- Over the last five years, Income towards Parent Company for PGEN reached as high as $95.0 million in Q3 2022 and fell as low as -$146.3 million in Q3 2025.
- Historically, Income towards Parent Company has averaged -$23.1 million across 4 years, with a median of -$23.6 million in 2024.
- Across the five-year window, Income towards Parent Company soared 2858.29% in 2022 and slumped 510.33% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at $95.0 million in 2022, then tumbled by 120.76% to -$19.7 million in 2024, then fell by 19.14% to -$23.5 million in 2025, then soared by 66.26% to -$7.9 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$7.9 million in Q1 2026, -$23.5 million in Q4 2025, and -$146.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Precigen | 1.95 Bn | 1.95 Bn | 20.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.93 Mn |
| Dec 31, 2025 | -23.50 Mn |
| Sep 30, 2025 | -146.34 Mn |
| Jun 30, 2025 | -26.64 Mn |
| Mar 31, 2025 | -54.15 Mn |
| Dec 31, 2024 | -19.73 Mn |
| Sep 30, 2024 | -23.98 Mn |
| Jun 30, 2024 | -58.79 Mn |
| Mar 31, 2024 | -23.74 Mn |
| Sep 30, 2022 | 95.02 Mn |
| Jun 30, 2022 | 8.42 Mn |
| Mar 31, 2022 | 4.65 Mn |
| Dec 31, 2021 | 1.66 Mn |
| Sep 30, 2021 | -3.45 Mn |
| Jun 30, 2021 | 10.89 Mn |
| Mar 31, 2021 | 4.53 Mn |
| Dec 31, 2020 | -1.31 Mn |
| Sep 30, 2020 | -1.97 Mn |
| Jun 30, 2020 | -27.65 Mn |
| Mar 31, 2020 | -35.15 Mn |